Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Anemia of Chronic Kidney Disease
Interventions
DRUG

Recombinant human erythropoietin

Dose, route and schedule was kept same as previous erythropoietin dose at randomization; adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.

DRUG

Darbepoetin Alfa

Dose conversion (100U erythropoietin = 0.42 mcg darbeopoetin). DA dose was kept once weekly (QW) if previously receiving rHuEpo ≥2 times a week, or Q2W if previously receiving rHuEpo \<2 times a week. Dose was adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.

Trial Locations (1)

110060

Sir Ganga Ram Hospital, New Delhi

All Listed Sponsors
lead

Rufaida Mazahir

OTHER

NCT04959578 - Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter